New antibody shows promise in shrinking HER2+ colorectal tumors before surgery
NCT ID NCT07405476
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether giving zanidatamab before surgery can shrink tumors in people with HER2+ colorectal cancer. About 38 participants will receive the drug intravenously, then undergo surgery. The study measures how much the tumor regresses and whether cancer returns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zanidatamab (a monoclonal antibody given intravenously)
What this could lead to
If it works, this could point toward a new treatment option for HER2+ colorectal cancer, potentially shrinking tumors before surgery and reducing recurrence risk.
What could go wrong
This is a small, early-phase trial with only 38 participants, so results may not apply to everyone. Zanidatamab may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory Decatur Hospital
RECRUITINGDecatur, Georgia, 30033, United States
-
Emory Saint Joseph's Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
-
Emory University Hospital
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Email: •••••@•••••
Contact
-
Emory University Hospital Midtown
RECRUITINGAtlanta, Georgia, 30308, United States